Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Nothing filed with the SEC yet Sea,
Stocktwits are suggesting an earnings report is due on the 13th Feb. It can't be worse than the last one!! 😁
The ambitious quarterly updates/reviews, tweets (x), strategy announcements and corporate gloss have been replaced by.......silence.
Instead, we've an agreement for 401 in return for shares in a company run by Tobias Wilson Waterworth (last seen on a jolly to Dubai - see LinkedIn). By profession he's a Chartered Accountant and was a Director of the now insolvent Atlantic Pharmaceuticals Ltd.
Stingray Bio, whose website only ever consists of "coming soon"....🙄
Meanwhile the EUDA/TRX/201 saga drags on ad finitum, the lab hasn't a single contract deemed worthy of an announcement and Cytolytix gobbles up more cash.
Stella leaves, then we're told Professor Hargreaves has stepped down from the SAB.
Other than the eternal optimist (PM2022), has anyone got anything positive to say? 🤣
It's a classic AIM "jam tomorrow" statement.
I've a few concerns, not least the higher price per ton, the huge volumes needed to generate profit and the massive manufacturing/delivery capability required.
However, I did listen to the presentation and the Board seem unfazed by the the size and cost of scaling up.
I bought a couple of shakers and like the product. In my view the shaker needs work to overcome the flour-like distribution onto food and the difficulty moderating portion sizes directly from the container.
Lots of development work needed but undoubtedly great potential.
GLA.
My big issue is the lack of new evaluations.
We've had one agreement with Stingray Bio who can't even be bothered to update their website, some three months since the announcement.
We were promised on the 28th September (Op Review RNS) that "Negotiations are ongoing with a number of parties to initiate evaluation agreements.".
Having received £1.86 million you would think the Board would be keen to sign a deal, or two, and begin utilising the lab to its full potential.
Thanks CM 👍
This chat board has been excellent the last few weeks with some really insightful posts, I have also enjoyed the Oakbloke's analysis.
Mrozzy posted a terrific link on the Salt board;
https://twitter.com/UKInvestorMAG/status/1754091869988889046
Judith seems the consumate professional, with an excellent CV.
Https://www.prnewswire.com/news-releases/innovative-eyewear-inc-commences-shipping-of-nautica-smart-eyewear-collection-302050664.html
"Nautica Smart Eyewear Collection has commenced shipping direct to customers in the US, with Canada and Mexico available shortly. Additionally, the product has begun shipping to select Nautica retailers in LATAM, Japan and Europe for review and potential inclusion in their product lineups. We believe this launch marks a significant milestone in the Company's growth and its strategic vision."
So Cliff subscribed for an additional
2.58 million shares in the IPO, which I assume he funded from the LUCY loan and BELL sale.
He's got to pay LUCY back within 90 days, I wonder how he plans to do that because the SALT holding is subject to a 12 month lock in.
Warrants are available, at over 10% of the SP.
He must be confident.
Come on everyone, let's play nicely.
We are all familiar with Lolly's salty viewpoint, can't we reserve the mudslinging until after the listing?
Not knowing the identity of the 60,000lb buyer is making me sweat, it could be a game changer.
Whatever your view the SP is up and it's an exciting time to be invested - so let's be pleasant, eh?
🙏
I hate to burst your bubble Sea, but;
Someone just sold 70 Lucy shares for 35 cents each in premarket, so it's down 17.44%! 🤣
Seaman's got his mojo back!! 🤣
Dennis has 10,000,000 shares, including £40,000 worth purchased at 0.8p last July.
Unlike a lot of AIM CEO's he has plenty of skin in the game and more to lose than many of us investors.
Personally, I believe in what he says.
Well, if Cliff is planning a big bang - it could be time.
a) release the name of the 60,000lb buyer to kickstart the Microsalt IPO.
b) LUCY boost SP over $1 by launching Reebok deal, thus avoiding delisting
c) BELL issue some decent numbers (an update is due).
d) We get some Guident revenues and/or a Revive sale.
Granted, it's all the stars aligning, but not impossible.
Cliff's raised cash for a reason, all will become clear by the weekend.
Hold for gold!! 🤣
Cox isn't bothered, they've just trousered £1.86 million for R&D and "brand development".
Income generation isn't part of the playbook.
Good points Top,
The other interesting event this week is that LUCY's six months deadline (for non-compliance with NASDAQ rules) expires on Friday.
They will have to boost the SP soon, or risk an appeal against a possible delisting.
What this IPO really needs is an announcement naming the food company who placed the 60,000lb order, with likely recurring revenue (see RNS from 22nd Dec).
EUDA have borrowed $500,000 dollars from Gilandi Limited, a British Virgin Islands company via a CLA with maturity dates of 31st Jan and 31st Mar 2024.
I assume they need this cash to keep afloat until the merger completes.
I might be wrong....
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317999141&type=HTML&symbol=EUDA&cdn=41708d83d16db596db8005627e69cbbb&companyName=Euda+Health+Holdings+Limited&formType=6-K&formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&dateFiled=2024-01-23
Sea,
What do you reckon Cliff wants the cash for? He just loaned £600,000 off LUCY.
Maybe he's spotted an opportunity too good to miss? Say, additional Microsalt inventory support for a big partner?
We can but hope.
PM,
"Bringing lots in and increasing costs further down the line is wrong and would show a complete lack of understanding"
Disagree; Dr Cox stated an ambition to bring in 3-4 new evaluation projects each year (ref: Half yearly report RNS), when he knew full well the funding position was precarious.
I'm anticipating you'll blame the failure to get 201 over the line for that.
This Board have pattern of promising but failing to deliver any shareholder value, you can't deny it.
PM,
Quote "you don't want too many compounds in the pipeline".
What? We are a drug development company, are we not?
The legacy assets have been farmed out to TRX, Ambrose and Stingray for nothing (as yet).
CLX was put into an SPV whilst shareholders were told "we are seeking partners" - it now requires another £400,000 R&D. Why waste money on an SPV before development was even completed?
We need more rounds in the chamber, otherwise we risk not hitting any targets at all.